Janina Krumbeck, PhD, discusses the clinical advantages of next-generation sequencing over traditional culture and how this untargeted diagnostic approach provides comprehensive pathogen ...

Tuberculosis (TB) is the world’s leading cause of death from a single infectious agent, affecting more than 10 million people each year and caused an | Genetics And Genomics ...

Natera NTRA announced the commercial launch of Zenith genomics, a next-generation whole genome sequencing assay designed to ...

Life sciences and diagnostics company Revvity has had a busy couple of years, playing a major role in the next-generation sequencing-based screening of newborns to better enable healthcare ...

Routine newborn screening (NBS) has transformed early disease detection. However, traditional biochemical tests limit the range of conditions that can be identified at birth. Next-generation ...

Every year, millions of newborns undergo routine screening as a preventive strategy to detect inherited disorders before symptoms emerge. Newborn screening (NBS) programs have traditionally relied on ...

Twice the output, half the runtime, and half the footprint of the UG 100® with greater flexibility and improved genomic coverage Introducing two new high-throughput instrument configurations ...

The global DNA sequencing market is projected to reach USD 40.02 billion by 2031, driven by declining sequencing costs, expanding clinical applications in oncology and rare diseases, and growing ...

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched the Twist TrueAmp ...